Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K. Yonesaka K, et al. Among authors: yokoyama t. Clin Lung Cancer. 2023 Sep;24(6):519-527.e4. doi: 10.1016/j.cllc.2023.05.008. Epub 2023 Jun 3. Clin Lung Cancer. 2023. PMID: 37344331 Clinical Trial.
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Hayashi H, Fukuyama H, Nishiyama A, Yokoyama T, Kuyama S, Umemura S, Kato Y, Nogami N, Segawa Y, Yasugi M, Tabata M, Tanimoto M. Hotta K, et al. Among authors: yokoyama t. J Thorac Oncol. 2010 Oct;5(10):1668-72. doi: 10.1097/JTO.0b013e3181f1c8cb. J Thorac Oncol. 2010. PMID: 20871267 Free article.
Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.
Ikeda S, Arita M, Misaki K, Mishima S, Takaiwa T, Nishiyama A, Ito A, Furuta K, Yokoyama T, Tokioka F, Noyama M, Yoshioka H, Ishida T. Ikeda S, et al. Among authors: yokoyama t. Springerplus. 2015 May 28;4:240. doi: 10.1186/s40064-015-1013-8. eCollection 2015. Springerplus. 2015. PMID: 26101728 Free PMC article.
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K. Oda N, et al. Among authors: yokoyama t. Clin Lung Cancer. 2017 Mar;18(2):241-244. doi: 10.1016/j.cllc.2016.07.003. Epub 2016 Jul 9. Clin Lung Cancer. 2017. PMID: 27506489 Clinical Trial.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F. Hata A, et al. Among authors: yokoyama t. Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7. Cancer. 2018. PMID: 30192383 Free article. Clinical Trial.
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K. Oda N, et al. Among authors: yokoyama t. Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1. Cancer Chemother Pharmacol. 2018. PMID: 30276451 Clinical Trial.
3,826 results